Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow HALOZYME THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for HALOZYME THERAPEUTICS, INC.

HALO

HALOZYME THERAPEUTICS, INC.

About HALOZYME THERAPEUTICS, INC.

Halozyme Therapeutics, Inc. develops innovative drug delivery and auto-injector technologies, primarily utilizing its ENHANZE platform with proprietary enzyme rHuPH20. It licenses its technology to biopharmaceutical partners for subcutaneous formulations, enhancing drug absorption and patient convenience. The company also markets proprietary products like Hylenex and XYOSTED, supporting collaborations with major pharma firms to improve injectable therapies and expand treatment options globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from HALOZYME THERAPEUTICS, INC.

1
1
HALOZYME THERAPEUTICS, INC. Halozyme Therapeutics Reports 42.2% Revenue Growth to $376.7 Million in Latest Quarter

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
HALOZYME THERAPEUTICS, INC. Halozyme Therapeutics Reports 52% Revenue Growth to $1.4 Billion in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
HALOZYME THERAPEUTICS, INC. Halozyme Therapeutics Reports 22% Revenue Growth to $354.3 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
HALOZYME THERAPEUTICS, INC. Halozyme Therapeutics Reports 41% Revenue Growth to $325.7 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
HALOZYME THERAPEUTICS, INC. Halozyme Therapeutics Reports 35% Revenue Growth to $264.9 Million in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
HALOZYME THERAPEUTICS, INC. Halozyme Therapeutics Reports 22% Revenue Growth to $1.015 Billion in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
HALOZYME THERAPEUTICS, INC. Halozyme Therapeutics Reports 34% Revenue Growth and Significant Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments